Drug Profile
MM A01 01
Alternative Names: MMA0101Latest Information Update: 28 Jan 2019
Price :
$50
*
At a glance
- Originator Myungmoon Pharm
- Class Antibodies; Antirheumatics
- Mechanism of Action Tumour necrosis factor alpha inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Rheumatoid arthritis
Most Recent Events
- 28 Jan 2019 No recent reports of development identified for clinical-Phase-Unknown development in Rheumatoid-arthritis in South Korea